Mitri Jad, Almeqdadi Mohammad, Karagozian Raffi
Department of Medicine, Saint Elizabeth's Medical Center, Boston, MA 02135, United States.
Division of Transplant and Hepatobiliary Disease, Tufts Medical Center, Boston, MA 02111, United States.
World J Hepatol. 2023 Aug 27;15(8):954-963. doi: 10.4254/wjh.v15.i8.954.
Alcohol-associated hepatitis (AAH) is a severe form of liver disease caused by alcohol consumption. In the absence of confounding factors, clinical features and laboratory markers are sufficient to diagnose AAH, rule out alternative causes of liver injury and assess disease severity. Due to the elevated mortality of AAH, assessing the prognosis is a radical step in management. The Maddrey discriminant function (MDF) is the first established clinical prognostic score for AAH and was commonly used in the earliest AAH clinical trials. A MDF > 32 indicates a poor prognosis and a potential benefit of initiating corticosteroids. The model for end stage liver disease (MELD) score has been studied for AAH prognostication and new evidence suggests MELD may predict mortality more accurately than MDF. The Lille score is usually combined to MDF or MELD score after corticosteroid initiation and offers the advantage of assessing response to treatment a 4-7 d into the course. Other commonly used scores include the Glasgow Alcoholic Hepatitis Score and the Age Bilirubin international normalized ratio Creatinine model. Clinical AAH correlate adequately with histologic severity scores and leave little indication for liver biopsy in assessing AAH prognosis. AAH presenting as acute on chronic liver failure (ACLF) is so far prognosticated with ACLF-specific scoring systems. New artificial intelligence-generated prognostic models have emerged and are being studied for use in AAH. Acute kidney injury (AKI) is one possible complication of AAH and is significantly associated with increased AAH mortality. Predicting AKI and alcohol relapse are important steps in the management of AAH. The aim of this review is to discuss the performance and limitations of different scoring models for AAH mortality, emphasize the most useful tools in prognostication and review predictors of recurrence.
酒精性肝炎(AAH)是一种由饮酒引起的严重肝病形式。在没有混杂因素的情况下,临床特征和实验室指标足以诊断AAH、排除肝损伤的其他原因并评估疾病严重程度。由于AAH的死亡率较高,评估预后是管理中的关键步骤。Maddrey判别函数(MDF)是首个确立的AAH临床预后评分系统,最早用于AAH临床试验。MDF>32表明预后不良,且开始使用皮质类固醇可能有益。终末期肝病模型(MELD)评分已用于AAH预后研究,新证据表明MELD可能比MDF更准确地预测死亡率。Lille评分通常在开始使用皮质类固醇后与MDF或MELD评分相结合,具有在治疗4 - 7天评估治疗反应的优势。其他常用评分包括格拉斯哥酒精性肝炎评分和年龄-胆红素-国际标准化比值-肌酐模型。临床AAH与组织学严重程度评分充分相关,在评估AAH预后时几乎没有肝活检的指征。表现为慢性肝衰竭急性发作(ACLF)的AAH目前采用ACLF特异性评分系统进行预后评估。新的人工智能生成的预后模型已经出现并正在AAH中进行研究。急性肾损伤(AKI)是AAH的一种可能并发症,与AAH死亡率增加显著相关。预测AKI和酒精复发是AAH管理中的重要步骤。本综述的目的是讨论不同AAH死亡率评分模型的性能和局限性,强调预后评估中最有用的工具,并综述复发预测因素。